Tagrisso (Osimertinib) Competitors and EGFR TKI Market Landscape

Tagrisso (osimertinib) is the reference product in first-line EGFR-mutated non-small cell lung cancer (NSCLC), and searches for “Tagrisso competitors” and the “osimertinib market” reflect that. This guide maps the competitive picture as of November 4, 2026, using company reports, FDA documents and trade press. It deliberately contains no third-party market-size forecasts, which could not be verified from primary sources.

Updated November 4, 2026.

How big is Tagrisso, according to AstraZeneca?

In its 9M and Q3 2026 results, published October 30, 2026, AstraZeneca reported Tagrisso revenue of $2,087 million in the third quarter (up 12%) and $5,862 million for the first nine months (up 10% at actual exchange rates, 8% at constant exchange rates). Its commentary describes Tagrisso as the leading combination regimen in first-line NSCLC based on FLAURA2 (AstraZeneca Form 6-K). Tagrisso’s label spans metastatic first-line use (with and without chemotherapy), adjuvant use and unresectable stage III disease after chemoradiation, as summarized in our trial guide.

Who is the main branded competitor?

Johnson & Johnson’s Rybrevant (amivantamab) plus Lazcluze (lazertinib) was approved by the FDA on August 19, 2024 for first-line exon 19 deletion or L858R disease. In MARIPOSA, per the FDA label, median PFS by blinded central review was 23.7 months versus 16.6 months for osimertinib (HR 0.70), and the OS HR was 0.75, with a median not reached versus 36.7 months (FDA Rybrevant label). The label also carries a venous thromboembolism warning with prophylactic anticoagulation recommended for the first four months. The FDA approved subcutaneous Rybrevant Faspro on December 17, 2025 for all intravenous indications (FDA), and J&J announced on February 17, 2026 an FDA-approved once-monthly schedule with Lazcluze starting at week 5, supported by the phase 2 PALOMA-2 study (J&J). J&J’s Q3 2026 release (October 13, 2026) lists Rybrevant/Lazcluze as an oncology growth driver but, in the text reviewed, gives no product-level dollar figure.

How does the FLAURA2 combination fit?

AstraZeneca is also competing with itself: Tagrisso plus pemetrexed and platinum chemotherapy was approved February 16, 2024. FLAURA2 reported median PFS of 25.5 versus 16.7 months for Tagrisso alone (HR 0.62) (FDA), and the final OS analysis reported 47.5 versus 37.6 months (HR 0.77) (ASCO Post). Cross-trial comparisons with MARIPOSA are not randomized head-to-head evidence, and populations and follow-up differ. See Tagrisso with chemotherapy (FLAURA2) for that regimen in detail.

How to read the competitive structure

From a competitive-intelligence view, the pressure on Tagrisso comes in three different forms, and they should not be conflated. The first is direct first-line competition, where MARIPOSA is the only randomized comparison against osimertinib in this article, and its safety profile differs from Tagrisso’s. The second is lifecycle extension by the incumbent itself: combination regimens, earlier-stage indications and MET-directed pairings. The third is later-line competition for patients whose disease progresses, where antibody-drug conjugates and bispecific antibodies are positioned. Each form has its own evidence standard, and a result in one does not carry over to the others. Formulation and schedule are a fourth, quieter axis: J&J’s subcutaneous and monthly options target the administration burden of the antibody component, while Tagrisso remains a once-daily tablet.

What other agents are in play?

• Savolitinib (Orpathys) plus Tagrisso: AstraZeneca’s Q3 report states SAFFRON (second-line or later, MET overexpression or amplification) met its primary endpoint versus platinum chemotherapy (PFS HR 0.55; median 7.6 vs 5.4 months), as did the China-only SANOVO first-line trial in MET-overexpressing disease (PFS HR 0.56 overall; median 24.9 vs 13.8 months versus Tagrisso alone). Both were presented at ESMO 2026. The report lists no regulatory filings for them.
• Antibody-drug conjugates: Datroway (datopotamab deruxtecan) received FDA accelerated approval on June 23, 2025 for EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum chemotherapy, with a pooled response rate of 45% (FDA). TROPION-Lung14 (first-line with osimertinib) and TROPION-Lung15 are ongoing; no results have been announced. See also the Enhertu ADC landscape.
• Older TKIs: the FDA announced the first generic afatinib (Gilotrif) tablets on July 14, 2026 (FDA), a reminder that earlier-generation EGFR TKIs are already in generic competition.
• Firmonertinib (ArriVent): in exon 20 insertion NSCLC, phase 3 FURVENT did not meet its PFS endpoint by blinded central review (October 6, 2026; CancerNetwork). A separate trial, ALPACCA, in other EGFR mutations compares it with osimertinib or afatinib and is ongoing.
• PD-(L)1/VEGF bispecifics: Summit reported that the FDA accepted its ivonescimab application for EGFR-mutated non-squamous NSCLC after TKI therapy with a PDUFA date of November 14, 2026; see our ivonescimab article.

One data caveat for analysts: AstraZeneca’s figures are product revenue as reported, while J&J’s EGFR franchise is reported inside broader oncology lines in the text reviewed, so the two companies’ EGFR revenues cannot be compared directly from the documents used for this article.

What to watch next

• Nov 14, 2026: FDA action date for ivonescimab in EGFR-mutated NSCLC after TKI (company-reported; this has not happened as of November 4).
• Not dated: TROPION-Lung14 and TROPION-Lung15 readouts; ALPACCA; any filings for savolitinib plus Tagrisso.
• Label updates: OS-based label changes and any new Rybrevant indications.

Patent and exclusivity timelines for Tagrisso are not stated here because only third-party aggregators, whose dates conflict, were found; the FDA Orange Book and AstraZeneca’s annual report are the places to check. For context, see our osimertinib landscape article.

Next step

For ongoing monitoring of competitors in biomarker-defined lung cancer, Oncology Resource Group offers ONCRG Sentinel.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.